Muscle MRI in Becker Muscular Dystrophy & in Limb-girdle Muscular

Status Completed

Clinical Trial Summary

The purpose of this study is to investigate the paradoxical muscle enlargement in the calves and tongue seen in patients affected by Becker muscular dystrophy and Limb-girdle muscular dystrophy type 2I.

The enlarged calves' muscle quality will be assessed primarily on the basis of the muscle structure on MRI and based on a calculation of muscle strength per cross-sectional area.The findings will be compared with results from non-affected controls.

Additionally we want to describe the tongue muscle appearance on T1-weighted MRI.

Clinical Trial Description

The purpose of this study is to investigate the paradoxical muscle enlargement seen in patients affected by Becker muscular dystrophy and Limb-girdle muscular dystrophy type 2I.

Becker and limb-girdle muscular dystrophies are both hereditary muscular disorders. Both diseases appear clinically with shrinkage and muscle weakness of the muscles around the shoulder girdle and pelvis, while muscle hypertrophy of the calves and tongue is seen.

The quality of the enlarged calves has to the investigators knowledge not previously been described, and their hypothesis is that the normal correlation between muscle strength and muscle cross-section is absent in the calf muscles. Thus the investigators hypothesis suggests that there is no actual hypertrophy of the calf muscles, but rather a pseudohypertrofy with reduced force per cross-sectional area. With a picture of increased fat infiltration and disorganized muscle fibers.

The enlarged calves' muscle quality will be assessed primarily on the basis of the muscle structure on MRI (assessed on both T1 imaging, 3-point Dixon scans, and diffusion tension imaging), and based on a calculation of muscle strength per cross-sectional area. Isokinetic muscle dynamometry (Biodex-4) will be used to measure muscle strength. The findings will be compared with results from non-affected controls.

Additionally the investigators want to describe the tongue muscle appearance on T1-weighted MRI. ;

Study Design

Observational Model: Case Control, Time Perspective: Cross-Sectional

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02165358
Study type	Observational
Source	Rigshospitalet, Denmark
Contact
Status	Completed
Phase	N/A
Start date	June 2014
Completion date	January 2015

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT01168908` - Revatio for Heart Disease in Duchenne Muscular Dystrophy and Becker Muscular Dystrophy	Phase 2
Recruiting	`NCT01484678` - Magnetic Resonance Imaging and Biomarkers for Muscular Dystrophy
Completed	`NCT02847975` - Sodium Nitrate to Improve Blood Flow	Phase 1
Completed	`NCT02147639` - Effects of Sodium Nitrate on Blood Flow in Becker Muscular Dystrophy	Phase 2/Phase 3
Recruiting	`NCT02069756` - The Duchenne Registry
Completed	`NCT04585464` - A Study to Assess Safety, Tolerability, and PK of EDG-5506 in Healthy Volunteers and Becker Muscular Dystrophy Adults	Phase 1
Recruiting	`NCT04668716` - Brain Involvement in Dystrophinopathies Part 2
Completed	`NCT03236662` - (-)- Epicatechin Becker Muscular Dystrophy	Phase 2
Completed	`NCT01350154` - Effect of Modulating the nNOS System on Cardiac, Muscular and Cognitive Function in Becker Muscular Dystrophy Patients	Phase 2
Enrolling by invitation	`NCT06066580` - Open-Label Extension of EDG-5506 in Participants With Becker Muscular Dystrophy	Phase 2
Not yet recruiting	`NCT06363526` - Effectiveness of 5-week Digital Respiratory Practice in a Group of Children With Duchenne Muscular Dystrophy and Becker Muscular Dystrophy.	N/A
Recruiting	`NCT05409079` - Schulze Muscular Dystrophy Ability Clinical Study	N/A
Completed	`NCT01856868` - Use of (-)-Epicatechin in the Treatment of Becker Muscular Dystrophy (Pilot Study)	Phase 1/Phase 2
Completed	`NCT01557400` - Study of Ataluren for Previously Treated Participants With Nonsense Mutation Duchenne/Becker Muscular Dystrophy (nmDBMD) in Europe, Israel, Australia, and Canada	Phase 3
Recruiting	`NCT02109692` - Evaluation of Muscle miRNA as Biomarkers in Dystrophinopathies	N/A
Recruiting	`NCT03057002` - UTSW HP [13-C] Pyruvate Injection in HCM
Recruiting	`NCT04583917` - Brain Involvement in Dystrophinopathies Part 1
Withdrawn	`NCT03076814` - Functional Muscle Ischemia With Tadalafil Treatment in Becker Muscular Dystrophy	N/A
Completed	`NCT02207283` - PDE5 Inhibition to Alleviate Functional Muscle Ischemia in Becker Muscular Dystrophy	Phase 4
Completed	`NCT00873782` - Safety Study of Transvenous Limb Perfusion in Human Muscular Dystrophy	Phase 1

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Muscle MRI in Becker Muscular Dystrophy and in Limb-girdle Muscular Dystrophy Type 2I

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms